An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: Examples with warfarin and parathion

Toxicological Sciences

Volumn 70, Issue 1, 2002, Pages 120-139

  Gentry, P Robinan ^a   Hack, C Eric ^a   Haber, Lynne ^b   Maier, Andrew ^b   Clewell III, Harvey J ^a  

^a ENVIRON INTERNATIONAL CORPORATION   (United States)

^b Toxicology Excellence for Risk Assessment   (United States)

Author keywords

Genetic polymorphisms; Monte Carlo analysis; Parathion; Physiologically based pharmacokinetic (PBPK) modeling; Risk assessment; Toxicokinetic variability; Warfarin

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CYTOCHROME P450 2C9; PARATHION; WARFARIN; CYTOCHROME P450;

ALLELE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MONTE CARLO METHOD; NONHUMAN; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TOXICOKINETICS; ANIMAL; BIOLOGICAL MODEL; GENETIC POLYMORPHISM; GENETICS; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION; UNCERTAINTY;

ANIMALIA;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PARATHION; POLYMORPHISM, GENETIC; RISK ASSESSMENT; TISSUE DISTRIBUTION; UNCERTAINTY; WARFARIN;

EID: 0036850489     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/70.1.120     Document Type: Article

References (51)

1. Aithal, G. P., Day, C. P., Kesteven, P. J., and Daly, A. K. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719.
2. Baird, J. S., Cohen, J. T., Graham, J. D., Shyakhter, A. I., and Evans, J. S. (1996). Noncancer risk assessment: A probabilistic alternative to current practice. J. Hum. Ecol. Risk Assess. 2, 79-102.
3. Barnes, D. G., and Dourson, M. (1988). Reference dose (RfD): Description and use in health risk assessments. Regul. Toxicol. Pharmacol. 8, 471-486.
4. Black, D. J., Kunze, K. L., Wienkers, L. C., Gidal, B. E., Seaton, T. L., McDonnell, N. D., Evans, J. S., Bauwens, J. E., and Trager, W. F. (1996). Warfarin-fluconazole. II. A metabolically based drug interaction: In vivo studies. Drug Metab. Dispos. 24, 422-428.
5. Breckenridge, A., and Orme, M. (1973). Kinetics of warfarin absorption in man. Clin. Pharmacol. Ther. 14, 955-961.
6. Chan, E., McLachlan, A., O'Reilly, R., and Rowland, M. (1994). Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model. Clin. Pharmacol. Ther. 56, 286-294.
7. Choonara, I. A., Cholerton, S., Haynes, B. P., Breckenridge, A. M., and Park, B. K. (1986). Stereoselective interaction between the R enantiomer of warfarin and cimetidine. Br. J. Clin. Pharmacol. 21, 271-277.
8. Clewell, H. J., Gearhart, J. M., Gentry, P. R., Covington, T. R., VanLandingham, C. B., Crump, K. S., and Shipp, A. M. (1999). Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 19, 547-558.
9. Clewell, H. J., Gentry, P. R., Covington, T. R., and Gearhart, J. M. (2000). Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108(Suppl. 2), 283-305.
10. Clewell, H. J., Gentry, P. R., Gearhart, J. M., Allen, B. C., and Andersen, M. E. (2001). Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. Sci. Total Environ. 274, 37-66.
11. Costa, L.G., McDonald, B. E., Murphy, S. D., Omenn, G. S., Richter, R. J., Motulsky, A. G., and Furlong, C. E. (1990). Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103, 66-76.
12. Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., and Furlong, C. E. (1996). The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14, 334-336.
13. Diepgen, T. L., and Geldmacher-von Mallinckrodt, M. (1986). Interethnic differences in the detoxification of organophosphates: The human serum paraoxonase polymorphism. Arch. Toxicol. Suppl. 9, 154-158.
14. Dourson, M. L., Felter, S. P., and Robinson, D. (1996). Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24, 108-120.
15. Eaton, D. L., and Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol. Sci. 49, 156-164.
16. Eckerson, H. W., Wyte, C. M., and La Du, B. N. (1983). The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35, 1126-1138.
17. Furlong, C. E., Costa, L. G., Hassett, C., Richter, R. J., Sundstrom, J. A., Adler, D. A., Disteche, C. M., Omiecinski, C. J., Chapline, C., and Crabb, J. W. (1993). Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interact. 87, 35-48.
18. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., and Idle, J. B. (1995). Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392.
19. Gearhart, J. M., Jepson, G. W., Clewell, H. J., Andersen, M. E., and Conolly, R. B. (1994). Physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ. Health Perspect. 102(Suppl. 11), 51-60.
20. Haber, L. T., Maier, A., Gentry, P. R., Clewell, H. J., and Dourson, M. L. (2002). Genetic polymorphisms in assessing inter-individual variability in delivered dose. Regul. Toxicol. Pharmacol. 35, 177-197.
21. Haining, R. L., Hunter, A. P., Veronese, M. E., Trager, W. F., and Rettie, A. E. (1996). Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333, 447-458.
22. ICRP (1975). Metabolic data for manganese. In Report of the Task Group on Reference Man, pp. 71-72. International Commission on Radiological Protection, New York.
23. Ingelman-Sundberg, M. (2001). Genetic variability in susceptibility and response to toxicants. Toxicol. Lett. 120, 259-268.
24. Ingelman-Sundberg, M., Daly, A. K., and Nebert, D. W., Eds. (2002). Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available at: http://www.imm.ki.se/CYPalleles/. Accessed February 7, 2002.
25. IPCS (1994). Environmental Health Criteria 170. Assessing Human Health Risks of Chemicals: Derivation of Guidance Values for Health-Based Exposure Limits. International Programme on Chemical Safety, World Health Organization, Geneva.
26. IPCS (2001). Guidance document for the use of data in development of chemical-specific adjustment factors (CSAF) for interspecies differences and human variability in dose/concentration response assessment. International Programme on Chemical Safety, World Health Organization, Geneva. Available at: http://www.ipcsharmonize.org. Accessed January 10, 2002.
27. Jarabek, A. M. (1994). Inhalation RfC methodology: Dosimetric adjustments and dose-response estimation of noncancer toxicity in the upper respiratory tract. Inhal. Toxicol. 6, 301-325.
28. Kaminsky, L. S., and Zhang, Z.-Y. (1997). Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74.
29. Knudsen, L. E., Loft, S. H., and Autrup, H. (2001). Risk assessment: The importance of genetic polymorphisms in man. Murat. Res. 482, 83-88.
30. Kunze, K. L., Eddy, A. C., Gibaldi, M., and Trager, W. F. (1991). Metabolic enantiomeric interactions: The inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 3, 24-29.
31. Li, W. F., Costa, L. G., Richter, R. J., Hagen, T., Shih, D. M., Tward, A., Lusis, A. J., and Furlong, C. E. (2000). Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10, 767-779.
32. Linder, M. W., and Valdes, R., Jr. (2001). Genetic mechanisms for variability in drug response and toxicity. J. Anal. Toxicol. 25, 405-413.
33. Lipscomb, J., Teuschler, L., Swartout, J., and Kedderis, G. (2002). Incorporation of human interindividual enzyme expression and biotransformation variance into human health risk assessments. Toxicol. Sci. 66(Supp. 1), 154 (Abstract).
34. Luecke, R., and Wosilait, W. D. (1979). Drug elimination interactions: Analysis using a mathematical model. J. Pharmacokinet. Biopharm. 7, 629-641.
35. Luecke, R. H., Wosilait, W. D., Pearce, B. A., and Young, J. F. (1994). A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49, 90-103.
36. Meek, M. E., Newhook, R., Liteplo, R. G., and Armstrong, V. C. (1994). Approach to assessment of risk to human health for priority substances under the Canadian Environmental Protection Act. Environ. Carcinog. Ecotoxicol. Rev. C12, 105-134.
37. Miller, M. C., Mohrenweiser, H. W., and Bell, D. A. (2001). Genetic variability in susceptibility and response to toxicants. Toxicol. Lett. 120, 269-280.
38. Mueller, R. F., Hornung, S., Furlong, C. E., Anderson, J., Giblett, E. R., and Motulsky, A. G. (1983). Plasma paraoxonase polymorphism: A new enzyme assay, population, family, biochemical, and linkage studies. Am. J. Hum. Genet. 35, 393-408.
39. Renwick, A. G. (1993). Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10, 275-305.
40. Research Diagnostics, Inc. (2001). Cytochrome P450, native enzymes, human liver microsomes. Available at: http://www.researchd.com/cyp450/hlmicro.htm. Accessed November 8, 2001.
41. Rettie, A. E., Haining, R. L., Bajpai, M., and Levy, R. H. (1999). A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res. 35, 253-255.
42. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., and Korzekwa, K. R. (1994). Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42.
43. Sanghera, D. K., Saha, N., Kamboh, M. I. (1998). The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 136, 217-223.
44. Smolen, A., Eckerson, H. W., Gan, K. N., Hailat, N., and La Du, B. N. (1991). Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19, 107-112.
45. Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., and Rettie, A. E. (1997). Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7, 361-367.
46. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J., and Goldstein, J. A. (1996). The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349.
47. Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., and Echizen, H. (1998a). Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 63, 519-528.
48. Takahashi, H., Kashima, T., Nomoto, S., Iwade, K., Tainaka, H., Shimizu, T., Nomizo, Y., Muramoto, N., Kimura, S., and Echizen, H. (1998b). Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8, 365-373.
49. Taube, J., Halsall, D., and Baglin, T. (2000). Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819.
50. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R., and Watanabe, M. (1991). Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 82, 254-256.
51. U.S. EPA (1994). Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. EPA/600/8-90/066F. U.S. Environmental Protection Agency, Washington, DC.